Copy Link Print Information

Everolimus

(Synonyms: RAD001; SDZ-RAD)
119 Cited Publications
Customer Review

Based on 119 publication(s) in Google Scholar

Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.

For research use only. We do not sell to patients.

  • Purity: 99.85%
  • CAS No.: 159351-69-6
  • Formula: C53H83NO14
  • Molecular Weight:958.22
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Everolimus Chemical Structure
    Everolimus Chemical Structure
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
CAS No.: 159351-69-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Everolimus:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Everolimus

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All mTOR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Everolimus Chemical Structure
    Everolimus Chemical Structure
    1/16
  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019. [Abstract]

    Customer Validation
     ECa109 cells stably transfected with control shRNA or RICTOR shRNA were treated with RAD001 (10 μmol/L) or PP242 (2 μmol/L) for 48 h, and total proteins were extracted to analysis the expression of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K and p70S6K by Western blot (n=5).

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019. [Abstract]

    Customer Validation
     Total proteins in tumor tissues from nude mice were extracted and the expressions of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K (Thr389) and p70S6K were evaluated by Western blot (n=5). Values represent the mean±SD.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53. [Abstract]

    Customer Validation
     Combination of Everolimus with AZD2281 (left panel) and AZD2014 with AZD2281 (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Prostate. 2019 Jan;79(1):44-53. [Abstract]

    Customer Validation
     Treatment with sub-dose of Everolimus (10 nM), together with CQ (5 µM) increases the levels of Bax and cleaved PARP, and decreases the levels of Bcl-2 expression in both PC3 and LNPER cells.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19:12:911-920. [Abstract]

    Customer Validation
     786-O and A498 cell lines are treated by RAD001 with different concentrations for 24 hours. Immunoblotting shows that RAD001 induces autophagy indicators including upregulation of LC3-II/I and downregulation of p62 in a dose-dependent manner.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19:12:911-920. [Abstract]

    Customer Validation
     Immunoblotting demonstrates that AZD6244 can effectively restore upregulation of LC3-II/I and downregulation of p62 induced by RAD001 in 786-O and A498 cells.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Dec 8;10(12). pii: E1950. [Abstract]

    Customer Validation
     Western analysis of protein expression in cells treatmented with or without PLX4032 or RAD001.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     ED-40415 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     HUT-102 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     MT-2 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     ATL-43T cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1:408:43-54. [Abstract]

    Customer Validation
     Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM Everolimus. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Molecules. 2017 Dec 12;22(12). pii: E2207. [Abstract]

    Customer Validation
     p-AKT level in NRK cells treated with 5 nM RAD-001, 1 μM Resveratrol and their combination for 2 h and analyzed by Western blotting. Blots from 3 independent experiments are used for quantification.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Jan 28;11(1):e0147682. [Abstract]

    Customer Validation
     CHP-212 and SK-N-AS cells are treated with indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 are detected by specific anti-phospho antibodies. Loading is verified by specific antibodies to total AKT, ERK and anti-tubulin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Dec 8;6(39):42183-96. [Abstract]

    Customer Validation
     KNS-62 and T24 cells are treated with 250 nM AZD6244, 250 nM MEK162, 5 nM of Everolimus, 250 nM AKT8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2013 Jul 31;5(196):196ra99. [Abstract]

    Customer Validation
     Apoptosis and PI3K/Akt/mTOR pathway inhibition in cells treated with BYL719, RAD001, or the combination. Protein lysates from HCC1954 and JIMT-1 cells treated for 18 hours with 0.5 μM BYL719, 1 nM RAD001 or the combination are analyzed by immunoblotting against the indicated proteins. Data are shown as mean ± SEM. p-value is calculated using two-sided student’s t-test.

  • Everolimus